About Stem Cell Therapy for Blindness

Tentang Terapi Sel Punca untuk Kebutaan

Blindness no longer signifies an irreversible state. With advancements in regenerative medicine, individuals who have lost their sight now have the potential to perceive light once more.

Stem cells derived from a tissue called Wharton's Jelly, found within the umbilical cord of infants, offer hope for restoring some lost visual function or halting disease progression.

Aspiration to experience renewed light

Through WJ-MSC (Wharton's Jelly Mesenchymal Stem Cells) therapy, positive changes such as "experiencing light" and "brighter vision" have been reported.

For individuals experiencing vision loss, even the slightest perception of light represents invaluable hope. Leveraging the potential of stem cells through WJ-MSC therapy, patients have reported experiences akin to "light gradually illuminating a previously dark world."

For example, several patients undergoing therapy reported improved color differentiation and an enhanced ability to perceive approaching vehicles from a distance.

Furthermore, the speed of reading text on smartphones improves, and morning vision becomes clearer, with the effects lasting several hours.

It is akin to a closed door gradually opening, allowing light to begin to filter through.

Despite being a minor change, for this patient, it signifies a crucial first step towards emerging from a state of complete darkness, profoundly impacting their daily life and emotional well-being.

Key Point

  • WJ-MSC therapy has been associated with reported experiences of "sensing light" and "brighter vision."
  • The patient demonstrates improved color discrimination and motion perception.
  • Improved smartphone text reading speed and enhanced morning visual clarity.
  • Even in cases of complete blindness, partial recovery of vision remains possible.
  • Minor adjustments can have a significant positive impact on patients' lives and emotional well-being.

Regenerative Potential of the Umbilical Cord – What are Wharton's Jelly Stem Cells?

Mesenchymal Stem Cells from Wharton's Jelly (WJ-MSC) are "cells of hope" in regenerative medicine that combine extraordinary repair capabilities with high safety.

Mesenchymal Stem Cells from Wharton's Jelly (WJ-MSC) are a type of specialized stem cell derived from a gelatinous tissue known as Wharton's Jelly, found within the umbilical cord of a newborn. Post-natally, the umbilical cord is typically discarded; however, it harbors a rich source of stem cells with the capacity to repair and regenerate various body tissues.

WJ-MSCs are a type of mesenchymal stem cells (MSCs), characterized by their versatility in contributing to the repair of various tissues, including neural, vascular, bone, and cartilage. Moreover, utilizing cell culture technology, they can be expanded in large quantities, thus ensuring an adequate supply for therapeutic applications.

It is important to note that this cell possesses "immunological privilege," meaning it does not readily elicit rejection reactions even when allogeneically transplanted. This is because the surface of WJ-MSCs expresses very low levels of immunogenic marker molecules (such as MHC class II), which supports a high safety profile in clinical applications.

Furthermore, it has been demonstrated that the risk of tumor (cancer) transformation from WJ-MSCs is very low, with no reported cases of patients experiencing abnormal growths or lumps post-therapy. Ethically, there are no concerns as the cells are derived from umbilical cords that would otherwise be discarded, and this cell source is considered safe for use.

Thus, WJ-MSC, which integrates safety, efficacy, and ethical considerations, is currently garnering significant attention in regenerative medicine clinics worldwide and is regarded as a crucial 'key' for restoring vision in challenging conditions such as blindness.

Key Point

  • WJ-MSC is a stem cell derived from infant umbilical cord with high regenerative capabilities.
  • Exhibits 'immunological privilege,' rendering it less prone to rejection even from an allogeneic donor.
  • The risk of tumor transformation is extremely low, and its safety profile is excellent.
  • This cell source is ethically unobjectionable, as it is derived from umbilical cords that would otherwise be discarded.
  • Gained global attention in regenerative medicine as the "key" to restoring vision.

Mechanism of Stem Cell-Mediated Ocular Repair

WJ-MSC works as a "supporter" that protects the damaged retina, reactivates it, and awakens the ability to perceive light again.

Blindness is predominantly caused by damage or degeneration of retinal nerve cells (photoreceptor cells or optic nerve fibers) and retinal pigment epithelial cells, leading to impaired function. Herein, Wharton's Jelly-derived Mesenchymal Stem Cells (WJ-MSCs) play a crucial role. WJ-MSCs support injured ocular cells and promote the healing process towards functional restoration.

The properties demonstrated by WJ-MSC can be divided into two broad categories.

Cellular Repair Support (Paracrine Effect)

WJ-MSCs secrete a rich array of cytokines and growth factors to stimulate surrounding cells. These growth factors act directly on the retina to:

  • Alleviating inflammation
  • Preventing cell death (apoptosis)
  • Reducing oxidative stress (cellular rust)
  • Increasing blood flow and nutrient supply

Supporting the creation of an optimal environment for regeneration.

Additionally, WJ-MSCs possess a unique function: they transfer their mitochondria (the cell's powerhouses) to damaged cells to provide supplementary energy. This mechanism enables weakened photoreceptor cells to regain activity and enhances the function of surviving cells.

Differentiation into Ocular Cells (Differentiation Capacity)

Furthermore, WJ-MSCs have been reported to possess properties similar to photoreceptor cells or retinal pigment epithelial cells in vivo. In animal experiments, injected MSCs demonstrated light-sensing capabilities after engraftment into the retina, and hold significant promise for human application.

At this current stage, WJ-MSCs are considered to "assist surrounding cells in becoming stronger and stimulate self-repair" rather than "directly replacing lost cells." However, even this mechanism alone has brought hope for the restoration of visual function, a previously unattainable outcome through conventional methods, and represents a significant force in unlocking the future of regenerative medicine.

Key Point

  • WJ-MSC secrete cytokines and growth factors to suppress retinal inflammation and promote repair.
  • Transferring mitochondria to damaged cells to provide additional energy.
  • Certain WJ-MSCs may possess properties similar to photoreceptor cells or retinal cells.
  • The primary effect is "helping surrounding cells to become stronger and triggering self-repair" rather than direct cell replacement.
  • This offers hope for the restoration of visual function that was previously unattainable.

Pemulihan Penglihatan dan Penghentian Perkembangan
Bright Report from Clinical

WJ-MSC therapy not only improves vision but also brings hope for stopping progression towards blindness.

Visual enhancements and field of view improvements have been reported.

In clinical trials and real-world case reports, Wharton's Jelly-derived Mesenchymal Stem Cell (WJ-MSC) therapy has demonstrated improvement in vision and visual field.

The main changes reported are:

  • Retinal thickness recovered (the thinned part due to atrophy became thick again)
  • In a standard visual acuity test, on average, 10 more characters can be read.
  • In everyday life, the features and faces of people become more recognizable.
  • Retinal function was also confirmed to have recovered through electroretinogram (ERG) testing.

These changes instill in patients the realization that previously impossible tasks are now gradually becoming feasible.

The effect of inhibiting or decelerating development.

WJ-MSC therapy is not only anticipated to improve but also possesses the ability to halt progression. For example:

  • A confirmed case of genetic retinal disease with no progression over one year.
  • An example where the visual field and scotopic vision slightly improved.
  • Long-term follow-up research report demonstrating preserved vision and visual field for 3 years.

The cessation or slowing of progression, previously difficult to achieve, is now a reality through WJ-MSC therapy.

Expected Effectiveness Regardless of the Cause of Blindness

Another positive aspect is that the effects are not limited to specific diseases.

  • Genetic retinal disease
  • Diabetic retinopathy
  • Retinal disorders of various other causes

Improvements in vision and retinal health have been confirmed following Stem Cell Therapy across all these conditions, and it is hypothesized that the fundamental capacity to repair damaged tissue functions irrespective of the etiology of blindness.

Key Point

  • WJ-MSC therapy has been widely reported to demonstrate improvements in vision and visual field in clinical trials.
  • The retinal thickness was restored, and the patient was able to read 10 additional characters on the visual acuity test.
  • In progressive retinal diseases, there are numerous cases in which disease progression is arrested or decelerated.
  • Long-term follow-up data indicates that vision can be maintained for 3 years, with the expectation of sustained effects.
  • Providing hope to a diverse range of patients, irrespective of the underlying cause of their blindness.

Safety and Absence of Rejection Risk in Treatment

WJ-MSC therapy has very high safety, and the risk of immune rejection and cancerization is almost non-existent, which has been confirmed through numerous clinical studies.

When undergoing regenerative therapy, the most critical question is, "Is it truly safe?" In this regard, Wharton's Jelly-derived Mesenchymal Stem Cell (WJ-MSC) therapy is a highly safe option, substantiated by extensive clinical research.

The contributions of others are not easily disregarded.

Umbilical cord-derived WJ-MSCs possess characteristics that do not readily induce immune rejection. Typically, when allogeneic cells are introduced into the body, the immune system mounts a response, recognizing them as foreign entities. However, WJ-MSCs exhibit minimal expression of immunogenic markers on their cell surface, thereby facilitating their acceptance by the body.

Across all MSC clinical trials conducted worldwide, no serious immune rejection cases have been reported.

The risk of malignant transformation is also very low.

Stem cells possess a high proliferative capacity, which sometimes raises concerns about malignant transformation. However, it has been unequivocally confirmed that WJ-MSCs are non-tumorigenic.

No reports of abnormal masses or growths have emerged post-administration, and furthermore, large-scale analyses have not indicated an increased risk of cancer following MSC therapy.

No Side Effects and Naturally Compatible with the Body

In clinical trials, no serious adverse events were identified ocularly or systemically.

For example, in a study involving over 80 participants in Turkey, no serious adverse events occurred during the 6-month to 1-year follow-up period following WJ-MSC transplantation.

Upon the introduction of WJ-MSC into the body, it neither induces inflammation nor toxicity. Following the exertion of its therapeutic effects, the cell is naturally absorbed and eliminated. Its mode of action can be described as: naturally integrating with the body, performing its requisite functions, and subsequently dissipating discreetly.

Key Point

  • WJ-MSC exhibit low immunogenicity and can be safely administered even from allogeneic donors.
  • There is no risk of malignant transformation (tumor transformation), and its safety has been confirmed.
  • No serious side effects have been reported, and it is naturally absorbed by the body.
  • Robust safety has been substantiated by global clinical trials.
  • Treatment that demonstrates therapeutic efficacy and is well-tolerated.

Visual Function and Enhancement of Quality of Life (QOL)

WJ-MSC therapy shows potential to improve not only vision but also the level of independence and overall life activities.

The restoration of visual function leads to changes in daily life.

Expectations from Stem Cell Therapy extend beyond a mere improvement in visual acuity. The primary focus is an overall enhancement in the quality of life (QOL).

In patients receiving WJ-MSC therapy, it has been reported:

  • Reading and information gathering become easier.
  • Confidence in independent ambulation and exiting the home has increased.
  • Mental anxiety and depressive tendencies are reduced.

This improvement in daily living functions has been reported. The ability to read newspapers and books, previously challenging, is now possible, and the range of unassisted mobility (without a cane or personal assistance) has expanded.

Changes Observed by Others

Family and caregivers also reported:
  • The facial expression brightened.
  • Activity levels have increased.
  • The motivation to engage in activities outside the home is increasing.

The extent of visual recovery varies among individuals, but even minor improvements are directly correlated with the degree of independence in daily living and the willingness to engage socially.

Regenerative Medicine Contributing to Quality of Life Enhancement

Thus, WJ-MSC therapy transcends mere symptom relief and holds the potential to enhance the quality of life itself. Distinct from a mere improvement in clinical metrics, it yields a "life-changing transformation" that patients can personally experience, which constitutes its defining characteristic.

Key Point

  • WJ-MSC therapy has the potential to expand opportunities for activities of daily living and social participation.
  • Reading, walking, and outdoor engagement — the range of available activities is expanding.
  • Positive impacts are observed on psychological well-being, including reduced anxiety and increased motivation.
  • A treatment approach that holistically improves quality of life (QOL)

Conclusion: An Ever-Growing Light of Hope

Historically, blindness was a pronouncement of despair, signifying "never to see light again." However, with contemporary developments in regenerative medicine, blindness is no longer an irreversible destiny. With the advent of Wharton's Jelly Stem Cell Therapy, patients experiencing blindness now have the opportunity to restore their vision.

Research and clinical applications in this field are experiencing rapid global advancement, with knowledge continuously evolving. Stem Cell Therapy for blindness is not a myth, but an evolving medical reality. As medical practitioners, we are dedicated to working with utmost sincerity and enthusiasm to bring light to patients and their families expeditiously. We anticipate the imminent arrival of a day when patients afflicted with blindness can once again smile and perceive the beauty of light – and we are committed to continuous innovation to achieve this.

Contact Us
Referensi
Contact Us
Referensi